Summary

for people ages 18-100 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Pamela Munster

Description

Summary

Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Official Title

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreakTM 100)

Keywords

KRAS p.G12C Mutant Advanced Solid Tumors Neoplasms AMG 510

Eligibility

You can join if…

Open to people ages 18-100

  • Men or women greater than or equal to 18 years old.
  • Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12Cmutation identified through DNA sequencing.

You CAN'T join if...

  • Active brain metastases from non-brain tumors.
  • Myocardial infarction within 6 months of study day 1.
  • Gastrointestinal (GI) tract disease causing the inability to take oral medication.

Locations

  • Research Site accepting new patients
    San Francisco California 94115 United States
  • Research Site accepting new patients
    Santa Monica California 90403 United States

Lead Scientist

  • Pamela Munster
    Professor, Medicine. Authored (or co-authored) 120 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amgen
Links
AmgenTrials clinical trials website
ID
NCT03600883
Phase
Phase 1/2
Study Type
Interventional
Last Updated